Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
| Author | |
|---|---|
| Abstract |
:
The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax) between RTXM83, a proposed rituximab biosimilar, and its reference product, using a population PK model approach. |
| Year of Publication |
:
2018
|
| Journal |
:
Cancer chemotherapy and pharmacology
|
| Date Published |
:
2018
|
| ISSN Number |
:
0344-5704
|
| URL |
:
https://dx.doi.org/10.1007/s00280-018-3524-9
|
| DOI |
:
10.1007/s00280-018-3524-9
|
| Short Title |
:
Cancer Chemother Pharmacol
|
| Download citation |
